Physician profile
Richard L Addes
NPI 1861569964
$6,364.40
in general payments reported to CMS, 2019-2025
34 companies · $936 in 2025
The $936 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $961 · 2020: $1,219 · 2021: $1,034 · 2022: $833 · 2023: $611 · 2024: $770 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,317.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $973.92 | 2019-2025 | Jardiance, Tradjenta |
| Novo Nordisk INC | $900.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $886.59 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $646.78 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $630.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $285.19 | 2020-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $249.76 | 2019-2022 | |
| Abbvie INC. | $229.42 | 2019-2025 | |
| Exact Sciences Corporation | $216.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $199.19 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $192.20 | 2020-2022 | |
| Glaxosmithkline, LLC. | $124.06 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.01 | 2024-2025 | Xifaxan, Trulance |
| Eisai INC. | $108.75 | 2020-2024 | |
| Medtronic Vascular, INC. | $78.31 | 2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $59.29 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $56.17 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $55.70 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.48 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $38.10 | 2019-2023 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $37.73 | 2021-2022 | |
| Renalytix Ai, INC. | $24.05 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Acerus Pharmaceuticals Corporation | $23.82 | 2022 | |
| Lucid Diagnostics INC. | $20.76 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.82 | 2023 | Quviviq |
| Almatica Pharma LLC | $19.82 | 2023 | Loreev Xr |
| Ipsen Biopharmaceuticals, INC | $19.07 | 2019 | |
| Esperion Therapeutics, INC. | $18.86 | 2021 | |
| Mallinckrodt Hospital Products INC. | $18.15 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.75 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.12 | 2019 | |
| Shield Therapeutics INC | $14.37 | 2024 | |
| Arbor Pharmaceuticals, INC. | $14.01 | 2019 | |
| Bausch Health US, LLC | $12.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Addes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.